ClinicalTrials.gg
TerminatedNCT01420679Updated Nov 19, 2021Results posted

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

A Phase 3 interventional study of Pralatrexate Injection in Peripheral T-cell Lymphoma, sponsored by Spectrum Pharmaceuticals, Inc. Terminated at 55 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral — none open to participants now, 1 under way, 1 of them phase 3. pralatrexate · Lymphoma, T-Cell, Peripheral.

Enrollment
11th of 11
21 · median 48
Started
2011
with 1 other
Phase 3
3 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
1 of 11
Spectrum Pharmaceuticals, Inc

Among the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral, this one is the 11th largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 3, and was the 4th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

None of the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral is open now. The open studies under Lymphoma, T-Cell, Peripheral, anywhere →

About pralatrexate

pralatrexate: first FDA approval 2009 (FOLOTYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral as a file.
02

Study summary

The purpose of this study is to see if pralatrexate extends response and survival following CHOP-based chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) and if pralatrexate improves response in patients with partial response following CHOP-based chemotherapy. Patients will either receive pralatrexate or be under observation. All patients will receive vitamins B12 and folic acid and attend regular clinic visits to evaluate their disease and health.

Read the detailed description

This was an international, multi-center, randomized, Phase 3, open-label study of sequential pralatrexate versus observation in patients with previously undiagnosed PTCL who have achieved an objective response following initial treatment with CHOP-based chemotherapy.

Upon documentation of completion of an objective response following at least 6 cycles of a designated CHOP-based chemotherapy confirmation of histopathology by independent review, and confirmation that all eligibility criteria were met, patients were randomized in a 2:1 ratio to either pralatrexate or observation, according to a permuted block design with stratification factor of Tumor Response per Investigator at completion of CHOP-based therapy (Complete Response [CR] vs Partial Response [PR]).

All patients who receive at least 1 dose of pralatrexate were followed for safety through 35 (± 5) days after their last dose of pralatrexate or until all treatment-related AEs have resolved or returned to baseline/Grade 1, whichever is longer, or until it was determined that the outcome does not change with further follow-up.

03

Conditions studied

  • Peripheral T-cell Lymphoma

Keywords

  • Lymphoproliferative Disorders
  • Lymphoma
  • Non-Hodgkin's Lymphoma
  • T-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has one of the following peripheral T-cell lymphoma (PTCL) subtypes confirmed by an independent central pathology reviewer, using the Revised European American Lymphoma World Health Organization disease classification:

    • T/natural killer (NK)-cell leukemia/lymphoma
    • Adult T-cell lymphoma (TCL)/leukemia (human T-cell leukemia virus 1+)
    • Angioimmunoblastic TCL
    • Anaplastic large cell lymphoma (ALCL), primary systemic type, excluding anaplastic lymphoma kinase positive (ALK+) with International Prognostic Index (IPI) score less than 2 at initial diagnosis and complete response (CR) after CHOP-based therapy
    • PTCL-unspecified
    • Enteropathy-type intestinal lymphoma
    • Hepatosplenic TCL
    • Subcutaneous panniculitis TCL
    • Transformed mycosis fungoides (tMF)
    • Extranodal T/NK-cell lymphoma nasal or nasal type
    • Primary cutaneous gamma-delta TCL
    • Primary cutaneous CD8+ aggressive epidermic cytotoxic TCL
  • Documented completion of at least 6 cycles of CHOP-based therapy:

    • CHOP 21
    • CHOP 14
    • CHOP + etoposide
    • Other CHOP variants: substitution allowed for 1 component with a drug of the same mechanism of action. Additional components, except alemtuzumab, are allowed. Rituximab may be added if not given within 3 cycles of randomization.
  • Patient has achieved CR or partial response (PR) per per investigator's assessment following completion of CHOP-based therapy and has had radiological assessment within 21 days prior to randomization.
  • performance status less than or equal to 2.
  • Adequate blood, liver, and kidney function as defined by laboratory tests.
  • Women of must have a negative serum pregnancy test within 14 days prior to randomization and agree to practice a medically acceptable regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate.
  • Men who are sexually active, including those with a pregnant partner, must agree to practice a medically acceptable barrier method contraceptive regimen (eg, condoms) while receiving pralatrexate and for 90 days after the last administration of pralatrexate.
  • Has given written .

Exclusion criteria

Exclusion Criteria:

  • Patient has:

    • Precursor T/NK neoplasms
    • ALCL (ALK+) with IPI score less than 2 at initial diagnosis and CR after CHOP-based therapy
    • T cell prolymphocytic leukemia
    • T cell large granular lymphocytic leukemia
    • Mycosis fungoides, except tMF
    • Sézary syndrome
    • Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis
  • If there is a history of prior other than those below, must be disease free for at least 5 years. Patients with malignancies listed below less than 5 years before study entry may be enrolled if they have received treatment resulting in complete resolution of the cancer and have no clinical, radiologic, or laboratory evidence of active/recurrent disease.

    • non-melanoma skin cancer
    • carcinoma in situ of the cervix
    • localized prostate cancer
    • localized thyroid cancer
  • Receipt of prior chemotherapy (CT) or radiation therapy (RT) for PTCL, other than a single allowed CHOP regimen, except:

    • Patients with nasal NK lymphoma who received local RT less than 4 weeks prior to randomization.
    • Patients with tMF who received 1 systemic single-agent CT (except methotrexate) prior to transformation.
  • Prior exposure to pralatrexate.
  • Receipt of systemic within 3 weeks of study treatment, unless patient has been taking a continuous dose of 10 mg/day or less of oral prednisone or equivalent for at least 4 weeks or as part of a CHOP prednisone taper.
  • Planned use of any treatment for PTCL during the course of the study.
  • Patient has:

    • (HIV)-positive diagnosis with a of less than 100 mm3 or detectable viral load within past 3 months and receiving anti-retroviral therapy.
    • (HBV)-positive serology and is receiving interferon therapy or has liver function test results outside the parameters of study inclusion criteria. Other antiviral therapies are permitted if at a stable dose for at least 4 weeks.
    • (HCV) virus with detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy.
    • Symptomatic central nervous system or lesions requiring treatment.
    • Uncontrolled hypertension or congestive heart failure Class III/IV per the 's Heart Failure Guidelines
    • Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness impairing the ability of the patient to receive protocol treatment.
  • Major surgery within 2 weeks prior to study entry, except for line placement or procedure.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Pralatrexate

    Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.

    Drug: Pralatrexate Injection

  • No intervention
    Observation

    Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.

Interventions

  • Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride). Initial dose: 30 mg/m2 Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met.

    Also known as: FOLOTYN, PDX, Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time in days from randomization to the date of objective documentation of progressive disease (PD) or death, regardless of cause (date of PD or death - date of randomization + 1). PFS was to be assessed according to the International Workshop Criteria (IWC) without including positron emission tomography (PET). PD was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir. Participants who were alive without a disease response assessment of PD was to be censored at their last disease assessment date or the date of randomization, whichever was later. Date of progression was not to be imputed for participants with missing tumor assessments before an assessment of PD. Participants who withdraw from treatment prior to PD were to be followed for disease status whenever possible. Participants who have no response assessments after baseline were to be censored at randomization.

    Time frame: From randomization to the date of progression of disease or death due to any cause (up to 76 months)

  2. Overall Survival (OS)

    Overall survival was defined as the time in days from randomization to the date of death, regardless of cause (date of death - date of randomization + 1).

    Time frame: From randomization until death (up to 76 months)

Secondary outcomes

  1. Objective Response Rate

    Objective response rate was defined as percentage of participants with an objective response of complete response (CR) or partial response (PR), relative to disease status at the time of study entry. The percentage was to be calculated by dividing number of participants within each category of response by the number of participants with measurable disease at baseline. Objective response was assessed according to the IWC without including PET. CR was defined as complete disappearance all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR was defined as regression of measurable disease and no new sites.

    Time frame: Up to 2 years

  2. Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Serious Adverse Events (SAEs), and SAEs Leading to Discontinuation of Study Treatment, and Worst Grade Laboratory Abnormalities

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. AE included both serious and non- SAEs. An AE of "Hematology and Chemistry" was collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening and Grade 4 refers to life-threatening consequences.

    Time frame: From first dose of study drug to 35 (±5) days after last dose of study drug for the Pralatrexate Arm, and until 35 (± 5) days after the study treatment discontinuation for the Observation Arm (Up to 2 years)

07

Results

Posted Nov 19, 2021
Limitations and caveats
The study was prematurely terminated due to business reasons. There were no safety concerns that led to study closure. No efficacy assessments and analysis was conducted. A full statistical analysis and report were not completed.

Participant flow

Participant flow — Overall Study
MilestonePralatrexate ArmObservation Arm
Started147
Completed00
Not completed147
Withdrew: Disease progression32
Withdrew: Adverse event40
Withdrew: More than 28 days between doses of drug10
Withdrew: Patient decision10
Withdrew: Investigator decision12
Withdrew: Sponsor decision33
Withdrew: Other10

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the time in days from randomization to the date of objective documentation of progressive disease (PD) or death, regardless of cause (date of PD or death - date of randomization + 1). PFS was to be assessed according to the International Workshop Criteria (IWC) without including positron emission tomography (PET). PD was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir. Participants who were alive without a disease response assessment of PD was to be censored at their last disease assessment date or the date of randomization, whichever was later. Date of progression was not to be imputed for participants with missing tumor assessments before an assessment of PD. Participants who withdraw from treatment prior to PD were to be followed for disease status whenever possible. Participants who have no response assessments after baseline were to be censored at randomization.

Time frame:
From randomization to the date of progression of disease or death due to any cause (up to 76 months)

No measurements were reported for this outcome.

PrimaryOverall Survival (OS)

Overall survival was defined as the time in days from randomization to the date of death, regardless of cause (date of death - date of randomization + 1).

Time frame:
From randomization until death (up to 76 months)
Reported as:
Median · months
Overall Survival (OS)
monthsPralatrexate ArmObservation Arm
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryObjective Response Rate

Objective response rate was defined as percentage of participants with an objective response of complete response (CR) or partial response (PR), relative to disease status at the time of study entry. The percentage was to be calculated by dividing number of participants within each category of response by the number of participants with measurable disease at baseline. Objective response was assessed according to the IWC without including PET. CR was defined as complete disappearance all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR was defined as regression of measurable disease and no new sites.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Worst Grade Adverse Events (AEs), Deaths, Serious Adverse Events (SAEs), and SAEs Leading to Discontinuation of Study Treatment, and Worst Grade Laboratory Abnormalities

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. AE included both serious and non- SAEs. An AE of "Hematology and Chemistry" was collected and graded as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03, where Grade 3 refers to severe or medically significant but not immediately life threatening and Grade 4 refers to life-threatening consequences.

Time frame:
From first dose of study drug to 35 (±5) days after last dose of study drug for the Pralatrexate Arm, and until 35 (± 5) days after the study treatment discontinuation for the Observation Arm (Up to 2 years)
Reported as:
Count of participants · Participants
Number of Participants With Worst Grade Adverse Events (AEs), Deaths, Serious Adverse Events (SAEs), and SAEs Leading to Discontinuation of Study Treatment, and Worst Grade Laboratory Abnormalities
ParticipantsPralatrexate ArmObservation Arm
Participants with Any Treatment Emergent AEs146
Participants with Any Grade 3 - 4 AEs82
Participants with Treatment Emergent AEs Resulting in Deaths10
Participants with Treatment Emergent SAEs40
Participants with Any SAEs Leading to Drug Discontinuation20
Hematology:Higher Than Grade 3/4 Lab Abnormalities31
Chemistry:Higher Than Grade 3/4 Lab Abnormalities10

Adverse events

Collected over From first dose of study drug to 35 (±5) days after last dose of study drug for the Pralatrexate Arm, and until 35 (± 5) days after the study treatment discontinuation for the Observation Arm (Up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pralatrexate Arm3/14 (21.4%)4/14 (28.6%)14/14 (100%)
Observation Arm1/7 (14.3%)0/7 (0%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
EventPralatrexate ArmObservation Arm
Cardiac arrestCardiac disorders1/140/7
StomatitisGastrointestinal disorders1/140/7
Non-cardiac chest painGeneral disorders1/140/7
Subdural hematomaInjury, poisoning and procedural complications1/140/7
HyponatraemiaMetabolism and nutrition disorders1/140/7
Haemorrhage intracranialNervous system disorders1/140/7
Carotid artery occlusionNervous system disorders1/140/7
VIIth nerve paralysisNervous system disorders1/140/7
Confusional statePsychiatric disorders1/140/7
DyspnoeaRespiratory, thoracic and mediastinal disorders1/140/7
Most frequent other events
Showing 10 of 135
Most frequent other events
EventPralatrexate ArmObservation Arm
DiarrhoeaGastrointestinal disorders6/141/7
NauseaGastrointestinal disorders6/141/7
FatigueGeneral disorders6/142/7
ArthralgiaMusculoskeletal and connective tissue disorders6/141/7
CoughRespiratory, thoracic and mediastinal disorders5/143/7
StomatitisGastrointestinal disorders5/141/7
EpistaxisRespiratory, thoracic and mediastinal disorders5/140/7
VomitingGastrointestinal disorders4/140/7
Mucosal inflammationGeneral disorders4/140/7
Upper respiratory tract infectionInfections and infestations3/142/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pralatrexate ArmObservation ArmTotal
Median72.0 (51 to 83)61.0 (44 to 83)68.0 (44 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Pralatrexate ArmObservation ArmTotal
Female808
Male6713
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pralatrexate ArmObservation ArmTotal
Asian202
Black112
Arabic011
White10515
Missing101
08

Study locations

55 sites
  • Detroit Clinical Research Center, PC
    Novi, Michigan 48377, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Flinders Medical Center
    Bedford Park, South Australia 5042, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7001, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Saint Vincent's Hospital Melbourne
    Fitzroy, Victoria 3109, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Cabrini Health
    Malvern, Victoria 3144, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • AZ Sint-Jan
    Brugge, 8000, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Sunnybrook Health Science Centre
    Toronto, Ontario M4N 3M5, Canada
  • Hôpital du Sacré-Coeur de Montréal
    Montreal, Quebec H4J 1C5, Canada
  • Hôpital Morvan
    Brest, 29609, France
  • CHU Haut-Leveque
    Pessac, 33604, France
  • St James Hospital
    Dublin 8, Ireland
  • Shaare Zedek Medical Center
    Jerusalem, 91031, Israel
  • Hadassah Ein-Kerem Medical Centre
    Jerusalem, 91120, Israel
  • Rabin Medical Center
    Petach Tikva, 49100, Israel
  • Chaim Sheba Medical Center
    Tel Hashomer, 52621, Israel
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
    Meldola, Forli 47014, Italy
  • Az. Ospedaliera Universitaria S. Orsola Malpighi
    Bologna, 40138, Italy
  • Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Ospedale S. Maria delle Croci
    Ravenna, 48121, Italy
  • Università Cattolica del Sacro Cuore
    Roma, 00168, Italy
  • Az. Ospedaliera Università Senese
    Siena, 53100, Italy
  • Middlemore Hospital
    Otahuhu, Auckland 1640, New Zealand
  • Auckland City Hospital / Auckland University
    Auckland, 1010, New Zealand
  • Christchurch Hospital
    Christchurch, 8011, New Zealand
  • North Shore Hospital
    Milford, New Zealand
  • Klinika Nowotworów Ukladu Chlonnego Centrum Onkologii Instytut Marii Sklodowskiej-Curie
    Warszawa, Mazowieckie 02-781, Poland
  • Dept of Hematology and Transplantology
    Gdansk, 80-952, Poland
  • Małopolskie Centrum Medyczne
    Kraków, 30-510, Poland
  • Auxilio Mutuo Cancer Center
    San Juan, 00918, Puerto Rico
  • Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Complejo Hospitalario de Navarra, Servicio de Hematologia
    Pamplona, Navarra 31008, Spain
  • Complejo Hospitalario Universitario A Coruña- Hospital A Coruña
    A Coruña, 15006, Spain
  • Hospital General Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital de Madrid Norte-Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, 28222, Spain
  • Royal Cornwall Hospital
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Poole Hospital NHS Foundation Trust, Poole General Hospital
    Poole, Dorset BH15 2JB, United Kingdom
  • Derriford Hospital
    Plymouth, England PL68DH, United Kingdom
  • Sandwell & West Birmingham Hospitals NHS Trust
    West Bromwich, England B71 4HJ, United Kingdom
  • Antrim Area Hospital
    Antrim, Northern Ireland BT41 2RL, United Kingdom
  • NHS Greater Glasgow and Clyde Western Infirmary
    Glasgow, Scotland G11 6NT, United Kingdom
  • Belfast City Hospital
    Belfast, BT9 7AB, United Kingdom
  • Velindre Hospital
    Cardiff, CF14 2TL, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • Mount Vernon Cancer Centre
    Middlesex, HA6 2RN, United Kingdom
  • UHCW (University Hospital Coventry and Warwickshire)
    Warwick, CA34 5BW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2011 to primary completion in Dec 2017, 76 months.

Results were first posted in Nov 2021, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2011
First posted
Aug 22, 2011
StartActual
Aug 2011
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Results first posted
Nov 19, 2021
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01420679
Responsible party
Sponsor
First posted
Aug 22, 2011
Start date
Aug 2011
Primary completion
Dec 2017
Completion
Dec 2017
Results posted
Nov 19, 2021
Last update
Nov 19, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion